BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company SmithKline  Beecham  Biologicals S.  A., submitted  on 2  August  1995 to the  European 
Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA),  an  application  to  obtain  marketing 
authorisation  for  the  medicinal  product  TWINRIX  Adult,  in  accordance  with  the  Centralised 
procedure falling within the scope of Part A of the Annex to Council Regulation No. (EC) 2309/93 of 
22 July 1993. 
The CPMP confirmed the status of the British Rapporteur and of the Irish Co-Rapporteur: 
Rapporteur:  Dr. D. Jefferys 
Co-Rapporteur:  Dr. M. Teeling 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The Co-rapporteur’s initial full assessment report was circulated to all members of the CPMP 
on 9 November 1995. 
The Rapporteur’s initial full assessment report was circulated to all members of the CPMP on 
11 November 1995. 
The CPMP in its meeting on 19-20 December 1995, discussed the major issues related to this 
application; in particular the rationale for the clinical need for such a combined vaccine. The 
consolidated list of questions to be sent to the company was adopted. 
The CPMP consolidated list of questions was sent to the company on 21 December 1995. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on  the  13 
March 1996. 
The  Rapporteur’s  assessment  report  on  the  company  responses  was  circulated  to  all  CPMP 
members on 15 April 1996. 
The Co-rapporteur’s assessment report on the company responses was circulated to all CPMP 
members on 18 April 1996. 
Member  States  comments  on  the  Rapporteur  and  Co-rapporteur’s  assessment  reports  were 
received up to 10 May 1996. 
A meeting was held between the Rapporteur and Co-rapporteur on 13 May 1996 to discuss the 
outstanding  points.  A  breakout  session  on  pharmaceutical  matters  was  considered  to  be 
necessary to further discuss these outstanding points. 
The  company  provided  additional  information  addressing  the  outstanding  points  on  the  15 
May 1996. 
During the CPMP meeting on 20-22 May 1996, a breakout session on pharmaceutical matters 
took  place,  where  the  company  in  response  to  the  remaining  outstanding  issues  gave  oral 
explanations. 
The outcome of the breakout session was circulated at the CPMP meeting on 21 May 1996. 
The  CPMP  in  its  meeting  on  20-22  May  1996,  considered  the  responses  provided  by  the 
company  to  be  adequate  and  unanimously  granted  a  positive  opinion  for  Twinrix  Adult, 
monodose vial and syringe presentations.  
1/1 
©EMEA 2005 
 
 
 
 
